Colorectal cancer in review: the role of the EGFR pathway
作者： Muhammad W Saif
DOI: 10.1517/13543781003593962
关键词: Erlotinib 、 Cetuximab 、 Pertuzumab 、 Matuzumab 、 Colorectal cancer 、 Oncology 、 Gefitinib 、 Tyrosine kinase 、 Internal medicine 、 Panitumumab 、 Medicine
摘要: … there was no difference between these sites for EGFR FISH, HER2 FISH and KRAS results. … colorectal carcinoma should not receive anti-EGFR antibody therapy as part of their treatment…
informahealthcare.com参考文章(108)
W. Zhang, D. Yang, M. Capanu, E. Hollywood, M. Lue-Yat, E. Borucka, M. Azuma, M. Gordon, L. Saltz, H. Lenz, Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer Journal of Clinical Oncology. ,vol. 25, pp. 4128- 4128 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.4128
S. Tejpar, M. Peeters, Y. Humblet, H. Gelderblom, J. Vermorken, F. Viret, B. Glimelius, F. Ciardiello, O. Kisker, E. Van Cutsem, Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data Journal of Clinical Oncology. ,vol. 25, pp. 4037- 4037 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.4037
C. Tournigand, G. Lledo, J. Delord, T. André, F. Maindrault-Goebel, C. Louvet, W. Scheithauer, A. de Gramont, Modified (m)Folfox7/bevacizumab (B) or modified (m)Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR) Journal of Clinical Oncology. ,vol. 25, pp. 4097- 4097 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.4097
F. Nagashima, W. Zhang, M. Gordon, H. M. Chang, G. Lurje, E. Borucka, D. Yang, R. Ladner, E. Rowinsky, H. J. Lenz, EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144) Journal of Clinical Oncology. ,vol. 25, pp. 4129- 4129 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.4129
Srinivas Venkateswarlu, Dawn M Dawson, Patricia St Clair, Anjana Gupta, James KV Willson, Michael G Brattain, Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene. ,vol. 21, pp. 78- 86 ,(2002) , 10.1038/SJ.ONC.1205011
Edward S. Kim, Fadlo R. Khuri, Roy S. Herbst, Epidermal growth factor receptor biology (IMC-C225) Current Opinion in Oncology. ,vol. 13, pp. 506- 513 ,(2001) , 10.1097/00001622-200111000-00014
J. Baselga, P. Schöffski, F. Rojo, H. Dumez, F. J. Ramos, T. Macarulla, R. Cajal, O. Kisker, A. Van Oosterom, J. Tabernero, A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. ,vol. 24, pp. 3006- 3006 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.3006
Mentes Bb, Unsal D, Uner A, Ebinc Fa, Dursun A, Akyurek N, Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Experimental Oncology. ,vol. 27, pp. 225- 228 ,(2005)
John Mendelsohn, Targeting the epidermal growth factor receptor for cancer therapy. Journal of Clinical Oncology. ,vol. 20, ,(2002)
E. Van Cutsem, I. Lang, G. D'haens, V. Moiseyenko, J. Zaluski, G. Folprecht, S. Tejpar, O. Kisker, C. Stroh, P. Rougier, KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience Journal of Clinical Oncology. ,vol. 26, pp. 2- 2 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.2